{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:15:16Z","timestamp":1793499316528,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of insulin degludec\/liraglutide (IDegLira) versus insulin degludec (degludec) in Chinese people with type 2 diabetes (T2D) treated with basal insulin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>In DUAL II China, a randomized, double\u2010blinded, multicentre, treat\u2010to\u2010target trial, Chinese adults with T2D and HbA1c of 7.5% or more on basal insulin and metformin, with or without other oral antidiabetic drugs (OADs), were randomized 2:1 to 26\u2009weeks of treatment with either IDegLira (max. dose 50\u2009U degludec\/1.8\u00a0mg liraglutide) or degludec (max. 50\u2009U\/day), respectively, combined with metformin. At 26\u2009weeks, superiority of IDegLira over degludec was assessed for change in HbA1c (primary endpoint), and body weight and number of severe or blood glucose (BG)\u2010confirmed hypoglycaemic episodes (confirmatory secondary endpoints).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 453 participants were randomized to IDegLira (n\u00a0=\u00a0302) or degludec (n\u00a0=\u00a0151). Superiority was confirmed for IDegLira over degludec in HbA1c change (\u22121.9% vs. \u22121.0%, respectively, estimated treatment difference [ETD] [95% confidence interval]: \u22120.92% [\u22121.09; \u22120.75],\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u2009.0001), body weight change (\u22120.7\u00a0vs. +0.4\u00a0kg, respectively, ETD [95% CI]: \u22121.08\u2009kg [\u22121.63; \u22120.52],\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u2009.0002) and severe or BG\u2010confirmed hypoglycaemia (estimated rate ratio [95% CI]: 0.53 [0.30; 0.94],\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u2009.0297). The odds of achieving HbA1c less than\u00a07.0% without hypoglycaemia and\/or weight gain were greater with IDegLira than degludec (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u2009.0001 for all). Daily insulin dose at 26\u2009weeks was lower for IDegLira (34.3\u00a0U) than degludec (37.4\u00a0U) (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u2009.0014). No unexpected safety signals were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IDegLira may be an efficacious and well\u2010tolerated treatment intensification option for Chinese people with T2D uncontrolled on basal insulin and OADs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14522","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T06:20:05Z","timestamp":1628835605000},"page":"2687-2696","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["<scp>DUAL II<\/scp>\n                    China: Superior\n                    <scp>HbA1c<\/scp>\n                    reductions and weight loss with insulin degludec\/liraglutide (\n                    <scp>IDegLira<\/scp>\n                    ) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin"],"prefix":"10.1111","volume":"23","author":[{"given":"Yu","family":"Pei","sequence":"first","affiliation":[{"name":"Department of Endocrinology Chinese People's Liberation Army General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bue R.","family":"Agner","sequence":"additional","affiliation":[{"name":"Bispebjerg Hospital  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Luo","sequence":"additional","affiliation":[{"name":"Novo Nordisk China Pharmaceuticals  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Jinan Central Hospital, Shandong University  Jinan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Inner Mongolia People's Hospital  Hohhot China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Fifth People's Hospital of Shanghai  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology The Second Affiliated Hospital of Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Nishida","sequence":"additional","affiliation":[{"name":"Novo Nordisk Pharma Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Fuzhou General Hospital  Fuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3344-3540","authenticated-orcid":false,"given":"Yiming","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Chinese People's Liberation Army General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70189-5"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03069.x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2012.0305"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4557-7"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057319"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3158"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13132"},{"key":"e_1_2_9_10_1","unstructured":"Novo Nordisk. Xultophy\u00ae Summary of Product Characteristics. 2014.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xultophy-epar-product-information_en.pdf. Accessed July 28 2021."},{"key":"e_1_2_9_11_1","unstructured":"Novo NordiskXultophy\u00ae Prescribing Information. 2019.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208583s008s010s011lbl.pdf. Accessed July 28 2021."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70174-3"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0785"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0218-3"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13256"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1252"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1114"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13666"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13851"},{"key":"e_1_2_9_20_1","unstructured":"World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects: last amended by the 59th WMA General Assembly Seoul 2008.https:\/\/www.wma.net\/what\u2010we\u2010do\/medical\u2010ethics\/declaration\u2010of\u2010helsinki\/doh\u2010oct2008\/. Accessed July 28 2021."},{"key":"e_1_2_9_21_1","unstructured":"International Conference on Harmonisation Guideline. Integrated addendum to ICH e6(r1): guideline for good clinical practice ICH. E6(R2). 2016.https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf. Accessed July 28 2021."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4127"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0403-7"},{"key":"e_1_2_9_24_1","first-page":"2","article-title":"Chinese expert recommendation on basal insulin treatment in adult type 2 diabetes mellitus","volume":"25","author":"Ji L","year":"2017","journal-title":"Chin J Diabetes."}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14522","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14522","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:08:45Z","timestamp":1761869325000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/dom.14522"],"URL":"https:\/\/doi.org\/10.1111\/dom.14522","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"2021-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}